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Abstract
Purpose: AAV-mediated gene therapy in the rd10 mouse, with retinal degeneration caused by mutation in the rod cyclic
guanosine monophosphate phosphodiesterase b-subunit (PDEb) gene, produces significant, but transient, rescue of
photoreceptor structure and function. This study evaluates the ability of AAV-mediated delivery of X-linked inhibitor of
apoptosis (XIAP) to enhance and prolong the efficacy of PDEb gene-replacement therapy.
Methods: Rd10 mice were bred and housed in darkness. Two groups of animals were generated: Group 1 received sub-
retinal AAV5-XIAP or AAV5-GFP at postnatal age (P) 4 or 21 days; Group 2 received sub-retinal AAV5-XIAP plus AAV5- PDEb,
AAV5-GFP plus AAV5- PDEb, or AAV- PDEb alone at age P4 or P21. Animals were maintained for an additional 4 weeks in
darkness before being moved to a cyclic-light environment. A subset of animals from Group 1 received a second sub-retinal
injection of AAV8-733-PDEb two weeks after being moved to the light. Histology, immunohistochemistry, Western blots,
and electroretinograms were performed at different times after moving to the light.
Results: Injection of AAV5-XIAP alone at P4 and 21 resulted in significant slowing of light-induced retinal degeneration, as
measured by outer nuclear thickness and cell counts, but did not result in improved outer segment structure and rhodopsin
localization. In contrast, co-injection of AAV5-XIAP and AAV5-PDEb resulted in increased levels of rescue and decreased
rates of retinal degeneration compared to treatment with AAV5-PDEb alone. Mice treated with AAV5-XIAP at P4, but not
P21, remained responsive to subsequent rescue by AAV8-733-PDEb when injected two weeks after moving to a light-cycling
environment.
Conclusions: Adjunctive treatment with the anti-apoptotic gene XIAP confers additive protective effect to gene-
replacement therapy with AAV5-PDEb in the rd10 mouse. In addition, AAV5-XIAP, when given early, can increase the age at
which gene-replacement therapy remains effective, thus effectively prolonging the window of opportunity for therapeutic
intervention.
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Introduction
Retinitis pigmentosa (RP) encompasses a heterogeneous group
of inherited retinal dystrophies characterized by photoreceptor
dysfunction and eventual photoreceptor death [1]. Strategies
aimed at preventing the cell death with anti-apoptotic agents have
shown some success in animal models, but have not yet been
translated into practical treatments for humans [2]. Newly
introduced experimental therapies such as treatment with
neurotrophic factors [3,4] and targeted gene–replacement offer
hope for improved outcomes [5,6,7]. The latter approach is
particularly appealing in that a normal copy of the gene is
introduced that corrects a functional deficit caused by a loss-of-
function mutation. However, development of targeted gene-
replacement therapy is a daunting task, given that RP is known
to be caused by mutations in over 100 genes [8]. Thus, the clinical
reality is that patients will continue to experience disease
progression until a corresponding gene therapy vector can be
developed. Thus, there remains an urgent need for a comple-
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definitive treatment is developed. In essence, we need a way to
prolong the window-of-opportunity-for treating the disease.
The X-linked inhibitor of apoptosis (XIAP) is a key member of
the gene family of inhibitors of apoptosis. XIAP is involved in
binding to and suppressing the activity of caspases 3, 7, and 9 [9].
Previous studies have shown that adeno-associated viral (AAV)
constructs encoding XIAP exert protective effects in various
models of retinal injury and disease including retinal ischemia
[10], ganglion cell death induced by axotomy [11,12] or increased
intraocular pressure [13], chemotoxic insult [14,15], retinal
detachment [16], retinal cell transplantation [17], and in genetic
models of retinitis pigmentosa [18]. What is not yet known is
whether XIAP-protected cells can be subsequently rescued by
transduction with a vector carrying a normal copy of the disease-
causing mutant gene.
The retinal degeneration 10 (rd10) mouse is a model of
autosomal-recessive RP caused by a point mutation of the Pde6b
gene[19]. Death of photoreceptors in the rd10 mouse begins soon
after birth, with most photoreceptor cells lost by 5 weeks of age
[20,21]. Dark-rearing delays the onset of degeneration by as much
as 4 weeks [19], however, rapid onset of photoreceptor degener-
ation occurs as soon as the animals are moved to a normal 12 h/
12 h cycling light environment. The rd10 phenotype can be
rescued with sub-retinal injection of AAV- PDEb [22,23], and is
especially effective when dark-rearing is used to achieve onset of
gene transduction and maximal protein synthesis prior to onset of
the degeneration.
The goal of the present study is to determine if anti-apoptotic
therapy with AAV5-XIAP can prolong the window-of-opportunity
for treatment of a hereditary retinal degeneration. Our results
show that transduction of photoreceptors in the rd10 mouse with
AAV5-XIAP confers structural protection of the outer nuclear
layer. In addition, AAV5-XIAP treated photoreceptors can be
transduced subsequently with either AAV5- PDEb or AAV8-733-
PDEb, in effect showing that AAV5-XIAP can prolong the
window of opportunity for gene replacement therapy. We
conclude that adjunctive treatment with the anti-apoptotic gene
XIAP has an additive effect on gene-replacement therapy with
AAV- PDEb alone.
Methods
Animals
Rd10 mice, and C57BL/6 mice that served as wild-type
controls, were obtained from The Jackson Lab (Jackson Labora-
tories, Bar Harbor, ME, USA). Mice were bred and housed in the
University of Michigan, Kellogg Eye Center animal facility. All
animal experiments were conducted in accordance with the
ARVO statement for the Use of Animals in Ophthalmic and
Vision Research and approved by the University Committee on
the Use and Care of Animals of the University of Michigan.
Vectors and Experimental Animal Groups
AAV5-XIAP (AAV5-CBA-XIAP-wPRE, HA tagged XIAP),
AAV5-GFP (AAV5-CBA-GFP), AAV5- PDEb (AAV5-smCBA-
PDEb) and AAV8-733- PDEb (AAV8-smCBA- PDEb in which a
Y to F capsid amino-acid change was made at position 733) were
produced and purified as previously described [15–17,22,23].
Late-term (around embryonic day 14) pregnant rd10 females were
moved from a cyclic-light environment (12-hour light/12-hour
dark) into a continuously dark room. Two groups of animals were
generated: Group 1 received sub-retinal injection of AAV5-XIAP
or AAV5-GFP at postnatal age (P) 4 or 21 days; Group 2 received
sub-retinal injection of AAV5-XIAP plus AAV5-PDEb, AAV5-
GFP plus AAV5-PDEb, or AAV5-PDEb alone at age P4 or P21.
After injection, the animals were maintained for 4 weeks in the
dark before they were moved to a normal 12 h/12 h light/dark
cycling environment. A subset of animals in Group 1 received a
second sub-retinal injection of AAV8-733-PDEb at two weeks
after being moved to the light.
Sub-retinal Injection
Sub-retinal injections were performed as previously described
[17]. Age P4 pups were anesthetized by hypothermia. The eye lids
were cleaned with 70% ethanol using a cotton-tipped applicator
and the interface of the upper and lower lids were cut with a sterile
scalpel. A sclerotomy was made in the superior sclera just posterior
to the cornea using the tip of a 30-gauge needle. A tapered pulled
glass pipette was inserted into the sclerotomy across the vitreous to
the opposite wall of the eye until resistance was encountered. The
pipette was slightly retracted from that point to position it in the
sub-retinal space. The pipette was connected to a nanoinjector
(Nanoinjector II, Drummond Scientific Company), which allowed
for a slow injection of the vector (1 ul containing 1610
10 vector
DNA containing AAV particles) into the sub-retinal space.
Mice age P21 or older were anesthetized by intra-peritoneal
injection of an anesthetic cocktail that consisted of ketamine
(100 mg/ml, Fort Dodge Animal Health, USA), xylazine
(LLOYD, Inc., IA) and sterile PBS in the ratio of 8:8:34. The
dose of cocktail injected was 0.1 ml per 20 g body weight. The
sub-retinal injection was performed as described above with direct
visualization through a dissecting microscope. The other eye
remained uninjected. After all injections, 1% atropine eye drops
and chloramphenicol ophthalmic ointment were given. Only
animals with minimal surgical complications were retained for
further evaluation. At least four animals were included for each
time point of each experimental group.
Immunocytochemistry
Mice were sacrificed and the eyes enucleated before and at 1, 2,
3 and 6 weeks after moving to the light, as follows: Animals were
deeply anesthetized and then perfused transcardially with 4%
paraformaldehyde in PBS. Eyes were collected and immersion
fixed with 4% paraformaldehyde at room temperature for 30 min.
The cornea and lens were removed and the eyecup rinsed three
times in PBS, then transferred to 10% and then 20% sucrose in
PBS for 2 h each, before embedding in OCT (Tissue Tek) mixed
in a ratio of 1:1 with 20% sucrose. A cryostat was used to obtain
10 mm thick serial retina/RPE/choroid sections.
Sections were washed in PBS, blocked with 10% goat serum
and 0.1% Triton-X 100 for 1 hr, and incubated with primary
antibodies diluted with 10% goat serum overnight at 4uC. The
primary antibodies and working dilutions were as follows: anti–
PDEb (1:400, ABR-Affinity BioReagents, Golden, CO), mouse
monoclonal rho1D2 (1:1000, a kind gift from Dr. Robert Molday),
and anti-hemagglutinin (HA) (1:100, Roche Applied Science,
Laval, QC, Canada) that is used as an expression tag for the
AAV5-XIAP vector. After three 10-min rinses with 0.1% Triton-
X 100, sections were incubated for 90 min at room temperature
with secondary antibodies diluted 1:1000 in PBS containing 0.1%
Triton X-100. The secondary antibodies were: goat anti-mouse
IgG, Alexa Fluor 647, (Invitrogen, USA) and goat anti-rabbit IgG
(H+L) Alexa Fluor 546 (Invitrogen, USA), goat anti-rat Alexa
Fluor 488 (Invitrogen, USA). Sections were counter-stained with
ProLong Gold with DAPI (Invitrogen, USA) to reveal cell nuclei.
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Comparison
Retinal images were obtained using a confocal microscope
(Leica SP5, Leica Corp., Germany). Three representative sections
encompassing the optic nerve were used from each eye. The total
thickness of the outer nuclear layer (ONL) and retina (from the
outer edge of the ONL to the inner limiting membrane) was
measured in three places in each of three non-overlapping high-
power fields (406) images at the comparable area per section and
averaged for each eye. Photoreceptor inner and outer segments
were not included in the total retinal thickness measurement. The
thickness of the ONL was normalized to total retinal thickness,
thus minimizing possible variability in measurement between
samples that could be caused by differences in angle of sectioning.
For each experimental group, measurements were made on three
sections of 3 to 5 eyes; each eye was from a different animal.
Western Blot Analysis
Retinas were dissected from treated and untreated rd10 eyes at
various time points. Age-matched normal C57BL/6J eyes were
used as controls. Samples were homogenized in hypotonic buffer,
and the proteins separated by 10% SDS-PAGE and blotted onto
nitrocellulose. The membranes were incubated overnight with:
anti-PDEb (1:500, ABR-Affinity BioReagents, Golden, CO), anti-
HA(1:200, Roche Applied Science, Laval, QC, Canada), anti-
GC1(1:200, Santa Cruz Biotechnology, Inc.), anti-rho (1:400) (gift
from Dr. Barry Knox), anti-transducin (1:1000), or anti-PDEa
(1:300) (gifts from Dr. Jose Bubis). The blots were developed with
alkaline phosphatase development buffer supplemented with 1%
v/v BCIP and 1% v/v NBT. Treated, untreated rd10 and normal
C57BL/6J samples were compared on the same blot with
GAPDH as an internal loading control.
Caspase 3 Activity Assays
One cohort of mice that received sub-retinal AAV5-XIAP
injection at P4 was used for caspase 3 activity assays at 24 h after
moving to the light. Total retinal protein from AAV5-XIAP
treated or untreated eyes was extracted as previously described.
11
Caspase 3 activity was measured with a colorimetric assay kit
(Chemicon International, Billerica, MA), in accordance with the
manufacturer’s instructions. This assay is based on cleavage of the
pNA-DEVD substrate by activated caspase 3. For each group, the
data represented the average caspase 3 activity levels of protein
from 18 eyes.
Electroretinography
Full-field electroretinograms (ERGs) were recorded at various
time points (before and at 1, 2, 3 and 6 weeks after moving to the
light). Mice were dark-adapted overnight and prepared under
dim-red illumination. Animals were anesthetized with an intra-
peritoneal loading dose of ketamine and xylazine. Pupils were
dilated with topical 1% atropine and 0.5% tropicamide. Body
temperature was maintained at 37uC with a heating pad during
the course of the experiment. Corneal ERGs were recorded from
both eyes using gold wire loops with 0.5% tetracaine eye drops for
topical anesthesia and a drop of 2% methylcellulose for corneal
hydration. A gold wire loop placed in the mouth was used as
reference, and ground electrode was on the tail. ERGs were
recorded with a Ganzfeld configuration using the Espion e
2
recording system (Diagnosys, Lowell, MA) to brief xenon white
flashes. Responses were amplified at 1,0006 gain at 1.25 to
1000 Hz, and digitized at a rate of 2000 Hz. A notch filter was
used to remove 60 Hz line noise. Dark-adapted ERGs were
recorded at a dim flash of 22.31 log cd-s/m
2/flash with an inter-
stimulus interval (ISI) of 4 seconds, and 15 sweeps were averaged.
Three sets of recordings were obtained to ensure reproducibility. A
bright flash at 1.09 cd-s/m
2/flash, with a maximum of 10 sweeps/
average and ISI of 30 seconds were recorded to elicit a maximum
response. Light-adapted responses were recorded after 10 min of
adaptation to a white 32 cd/m
2 rod-suppressing background for a
flash intensity of 1.09 log cd-s/m
2/flash and three sets of 20 sweeps
averaged. The amplitudes of scotopic and photopic B-waves of
injected eyes were all normalized by dividing by the scotopic and
photopic B-waves of untreated eye of the same animal before
moving to the cycling light-dark environment to minimize
variability among individuals.
Statistical Analysis
Comparison of normalized ONL thickness (thickness of ONL/
thickness of retina) and normalized ERG B-wave amplitudes at
each time point for different vector treated groups were performed
using analysis of variance (ANOVA) to provide pairwise compar-
isons with Sheffe’s adjustment for multiple comparisons. Non-
parametric Kruskal-Wallis (K-W) tests were performed for overall
differences in normalized ONL thickness among the groups at
each time. Significance was defined as a p-value of less than 0.05.
Comparison of caspase 3 activity was performed using two-tailed
Student’s t-tests without assuming equal variance. Differences were
considered significant at P,0.05.
Results
AAV5-XIAP inhibits caspase activity and increases
photoreceptor survival in rd10 mice
To test the ability of AAV5-XIAP to transduce the photore-
ceptor cells and inhibit the downstream activation of apoptosis,
rd10 mice received a sub-retinal injection with AAV5-XIAP at P4
and were kept in the dark for 4 weeks to allow for gene
transduction and maximal protein synthesis. Injection with AAV5-
GFP served as a control. Western blotting confirmed that the
XIAP protein was overexpressed in the retinas of AAV5-XIAP
injected eyes and undetectable in the contralateral untreated eyes
(Figure 1A). Assays of caspase 3 activity 24 h after moving the
animals to the light showed significantly increased levels at 24 h in
rd10 mice as compared to wild type, and these increases were
significantly reduced by AAV5-XIAP treatment (Figure 1B,
p=0.04). Immunohistochemistry showed that the XIAP expres-
sion was confined to the photoreceptors and localized primarily to
their inner segments (Figure 1C-c), consistent with prior reports of
XIAP localization to this photoreceptor compartment [16,17].
GFP expression was present in the photoreceptor inner segments
and throughout the cell bodies (Figure 1C-b).
Retinas from rd10 mice treated with AAV5-XIAP at P4 showed
significant structural preservation as compared to those treated
with AAV5-GFP. Treated and untreated animals reared in
darkness showed nearly normal retinal structure (Figure 1C a–c).
However, after moving the animals to the light environment, both
the AAV5-GFP injected eyes and untreated eyes showed severe
degeneration (Figure 1C d–e). In contrast, retinas from mice
treated with AAV5-XIAP were protected, with significantly
greater photoreceptor preservation as compared to control or
GFP-treated animals (Figure 1C-e)
AAV5-XIAP provided greater photoreceptor protection when
animals were treated at P4 as compared to P21 (Figure 2, Top
Panel). Regardless of the age at treatment, the rate of decrease of
ONL thickness was significantly slower after AAV5-XIAP
transduction than after AAV5-GFP transduction (p,0.001), in
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week in the light environment. However, the morphology of the
XIAP-treated retinas was not normal, with photoreceptors
displaying a marked absence of outer segments. Western blots of
retinal protein extracts showed rhodopsin was present (data not
shown), but immunohistochemical analysis revealed only a diffuse
distribution of rhodopsin staining throughout the ONL and inner
segments (Figure 2, Bottom Panel).
The slower rate of degeneration found in eyes treated with
AAV5-XIAP at P4 as compared to P21 could reflect the fact that
the animals treated at P21 were 17 days older than the P4-treated
animals when moved to the light. This is consistent with our
analysis of visual transduction protein levels and scotopic ERGs,
which were significantly lower in animals dark-reared for two
months compared to one month (Figure 3A, B). The measurable
ERG response of dark-reared rd10 mice, despite the absence of a
functional PDEb subunit, can likely be attributed this to the
presence of a normal PDEa subunit, and its ability to act as a
substitute for the missing PDEb subunit [24]. After moving the
rd10 mice to the light environment, there was a complete loss of
ERG responses from both the untreated and GFP-treated animals
within several days. Though PDEa was still present, movement to
light resulted in a rapid loss of other visual transduction proteins
such as rhodopsin, transducin and guanylate cyclase 1 (Figure 3A).
Despite the slower rate of cell death in the AAV5-XIAP treated
animals, ERG responses were also lost, consistent with the
observed loss of photoreceptor outer segments in these animals
(data not shown).
AAV5-XIAP enhances AAV5- PDEb rescue of
photoreceptor structure and function
Consistent with the results of previous studies [22,23], sub-
retinal injection of AAV5-PDEb resulted in the expression of
Figure 1. Effects of subretinal injection of AAV5-XIAP, or a control AAV5-GFP construct, on rd10 mice treated at P4 and dark-reared
for 4 weeks post treatment before being moved to the light environment. A. Western-blot analysis shows expression of recombinant XIAP.
B. Caspase 3 activity assayed 24 hours after transfer from the dark-rearing to the light environment shows AAV5-XIAP reduced caspase 3 activity
levels in untreated rd10 retinas to levels found in control C57 mice. C. Retinal histology at 3 weeks after moving to the light environment shows
extensive degeneration of the ONL in untreated (a,d) and AAV5-GFP treated retinas (b,e; green shows localization of GFP), and significant
preservation of ONL thickness and cell counts in the AAV5-XIAP treated retinas (c,f; green showing localization of XIAP by staining of HA-tag).
doi:10.1371/journal.pone.0037197.g001
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the significant preservation of photoreceptor cell numbers
(Figure 4C,D). In contrast to treatment with AAV-XIAP, AAV-
PDEb treatment resulted in improved photoreceptor morphology,
including the presence of both inner and outer segments (Figure 5,
Top Panel). Furthermore, retinas treated with AAV-PDEb
exhibited normal localization of rhodopsin to the outer segments
(not shown). However, AAV-PDEb treated retinas still underwent
slow but significant photoreceptor degeneration. After 6 weeks in
the light environment, ONL thickness decreased by approximately
20 percent in both the P4 and P21 treated animals (Figure 4C,D).
Co-treatment with AAV5-XIAP significantly reduced the
degeneration of the AAV5- PDEb treated retinas in both the P4
and P21 cohorts (Figure 4C,D). At six weeks after moving to the
light, the ONL thickness of retinas co-treated with AAV5-XIAP
remained stable, with no detectable diminution as compared to
baseline (prior to moving to the light). Co-treatment of AAV5-
PDEb with the control vector AAV5-GFP showed a similar
pattern of photoreceptor degeneration after transfer to the light as
was observed in retinas treated with AAV5-PDEb alone.
Immunohistochemical analysis of co-treated retinas showed co-
localization of PDEb with XIAP or GFP, verifying the co-
transduction of cells with each of the two separate vectors (Figure 5,
Bottom Panel).
Treatment with AAV5-PDEb preserved retinal function, and
this was enhanced by co-treatment with AAV5-XIAP. Scotopic
and photopic ERGs were measured prior to moving animals from
dark-rearing to the light environment (time 0), and then at 1, 2, 3
and 6 weeks after moving to the light (Figure 6A,C). The
amplitudes of scotopic and photopic B-waves of injected eyes were
all normalized by dividing by the scotopic or photopic B-waves
amplitudes of untreated eye of the same animal at time zero, in
order to minimize the variability among animals. Untreated eyes
showed higher ERG responses compared to treated eyes at time
zero, suggesting that perhaps the surgical procedure or the AAV-
vector has a deleterious effect on the retina (Figure 6B,D). After
transferring to the light, however, the ERGs of untreated eye were
quickly extinguished, consistent with the rapid photoreceptor
degeneration (Figure 6B,D). Treatment with AAV5-PDEb at
either P4 or P21 preserved retinal function. Consistent with the
improved survival of photoreceptor cells in AAV5-PDEb treated
retinas with adjunctive AAV5-XIAP, these co-treated retinas had
improved ERG function as compared to retinas co-treated with
AAV5-GFP (Figure 6A,C). There was no significant difference in
the ERG responses of P4 versus P21 treated retinas.
Sequential treatment of AAV5-XIAP followed by AAV8-
733-PDEb
Rd10 mice in this treatment group received an initial sub-retinal
injection of AAV5-XIAP at age P4 or 21, were maintained for 4
weeks in the dark, and then moved to the light. After two weeks in
the light, the animals received a sub-retinal injection of AAV8-
733-PDEb into the same eye. The AAV8-733 serotype was used
for the second injection because of its more rapid and efficient
expression of transgene as compared to the AAV5 serotype [23].
Control animals received AAV8-733-PDEb at 2 weeks after
transfer to light, but without initial XIAP treatment. Histological,
immunohistochemical, and ERG analysis were performed at 4
weeks after the second sub-retinal injection (6 weeks after moving
to the light). The transduction efficiency of the sequential injection
of AAV vectors into the same eye was evaluated relative to sub-
retinal injection of AAV5-GFP in C57 mice followed by a second
injection of AAV8-733-CHERRY at matched experimental time
points. There was over 75% overlap of GFP and CHERRY
staining in photoreceptor cells, indicating that vectors of different
serotype, and which express different transgenes, can be delivered
sequentially into the same cell effectively (data not shown).
As described above, retinas treated with only AAV5-XIAP
exhibited a slower rate of ONL degeneration upon moving to the
light, as compared to control or untreated eyes. Subsequent
injection of AAV8-733-PDEb two weeks later prevented further
loss of photoreceptors in retinas that received the initial AAV-
XIAP treatment at P4 (Figure 7A). However, sequentially injected
animals treated with XIAP at P21 showed continued degenera-
tion. No structural preservation was seen in control retinas.
Western analysis of the retinas from animals injected with AAV-
XIAP at P4 showed that the levels of visual transduction proteins
were stabilized by the subsequent transduction with AAV8-733-
PDEb (Figure 7B). Histologic analysis of the P4-injected cohort at
the six week time point (four weeks after the second sub-retinal
injection) showed preserved photoreceptor cells but marked
disruption of the outer segment morphology (Figure 7C). XIAP
Figure 2. Effects of sub-retinal injection of AAV5-XIAP on
photoreceptor cell survival and rhodopsin expression in rd10
mice. Top Panel. The ratio of ONL thickness to total retinal thickness
in rd10 retinas transfected with AAV5-GFP or AAV5-XIAP. Animals
received the sub-retinal injection at either P4 or P21 and then were
maintained in the dark-rearing environment for 4 weeks before being
moved to the light environment (time=0). Bottom Panel. rd10 retina
after AAV5-XIAP treatment shows rhodopsin mislocalization throughout
the ONL and shortened outer segments. (Rhodopsin, purple; DAPI,
blue).
doi:10.1371/journal.pone.0037197.g002
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37197Figure 3. Retinal function and protein expression in 1 and 2 month-old dark-reared rd10 mice. A. Normalized scotopic ERG B-wave
responses showing age-dependent loss-of-function under conditions where ONL cell counts were preserved. B. Western blots of PDEa, transducin,
rhodopsin (Rho) and guanylate cyclase 1 (GC1) expression showing significant age-dependent losses occurring in the dark, and catastrophic losses
occurring 24 hours after moving to the light environment.
doi:10.1371/journal.pone.0037197.g003
Figure 4. Co-transduction of rd10 retinas with AAV5-PDEb and AAV5-XIAP at P4 and P21. A. Western blot of PDEb expression in AAV5-
PDEb transduced rd10 retinas compared to wild type (C57) retinas. B. Confocal imaging of isolated rod outer segments from AAV5-PDEb transduced
rd10 retinas showing expression of PDEb (red). C–D. Co-treatment of rd10 retinas with AAV5-XIAP and AAV5-PDEb showing improved survival of
photoreceptor cells compared to retinas treated with AAV5-PDEb alone or in combination with AAV5-GFP. C. Co-injection at PN4. D. Co-injection at
PN21.
doi:10.1371/journal.pone.0037197.g004
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distorted outer segments. Rhodopsin staining could also be
detected. However, no ERG activity was detected due, perhaps
at least in part, to the disorganization of photoreceptor structure
potentially caused by multiple sequential injections into the sub-
retinal space.
Discussion
Previous attempts to improve outcomes in hereditary retinal
degenerations using anti-apoptotic or neurotrophic therapies have
focused on evaluating their ability to prevent or slow rates of
photoreceptor cell death [2,25]. While important advances have
been made, this strategy has not yet proven itself to be a stand-
alone therapy. The reasons for this may vary, depending on the
disease-causing mutation, but could include the toxic build-up of
proteins or metabolic by-products, or the activation of secondary
death pathways which ultimately result in cell death [25]. Most
importantly, anti-apoptotic therapy cannot replace activity lost
due to loss-of-function mutations, so deficits will still exist even if
the cells survive. On the other hand, vector-mediated gene-
replacement is a relatively new therapeutic technique, and its
strengths and limitations in reconstituting function and promoting
long-term photoreceptor survival are not yet well established in a
broad range of different genetic models. The current study
explores the effect of combining these two approaches, and finds
that adjunctive use of XIAP can both extend the window-of-
opportunity and enhance the effects of gene-replacement therapy.
On its own, we find that subretinal injection of AAV5-XIAP
results in a delay of the catastrophic light-dependent photorecep-
tor-cell death occurring in rd10 mice, but it cannot preserve ERG
responses once the mice are moved from the dark to the light. The
presence of ERG responses in dark-reared rd10 mice, in which the
disease-causing mutation results in PDEb loss-of-function, likely
reflects the ability of PDEa to act as a surrogate in generating the
functional enzyme [24]. Even though photoreceptor nuclei and
inner segments are initially well preserved, the inability of AAV5-
XIAP to prevent loss of the ERG is likely due to the fact that the
shift to the light cycling environment results in rhodopsin
mislocalization and loss/shortening of outer segments. A second
explanation, and one that is not mutually exclusive, is that the
light-induced loss of key photoreceptor proteins, including
transducin and guanylate cyclase, precludes the generation of
adequate signal amplification for detection by ERG recordings.
As in earlier studies [22,23], we find that gene-replacement
therapy of rd10 mice using AAV5-PDEb can significantly postpone
light-dependent photoreceptor-cell death, but that degeneration
continues over time, albeit at much slower rates than in control
retinas. The reason for continued photoreceptor-cell death in
retinas treated with AAV5-PDEb is not known. One possibility is
that the AAV5 serotype of the vector used achieves only limited
expression of PDEb, resulting in inadequate control of cGMP
levels and increased vulnerability to apoptotic cell death.
Consistent with this notion, long-term survival of rd10 photore-
ceptor cells has been shown to be improved by introducing PDEb
using a mutant AAV8 (AAV8-733) construct that achieves rapid
and high-level expression of the recombinant protein [23].
ERG responses of rd10 mice are also preserved by AAV5-PDEb
sub-retinal injection, with or without XIAP co-treatment (see
below). This protection appears to be greater in animals injected at
P21 than P4, but this may simply reflect the way the data were
normalized to allow for inter-animal comparison. For each animal,
the ERG amplitudes (photopic or scotopic) measured at various
times after moving to the light environment were normalized to
those of the untreated-fellow eye at time zero (i.e. just before
leaving the dark-rearing environment). Thus, at time zero, animals
treated at P21 were older and had lower ERG amplitudes than
animals treated at P4. When normalized for the reduction in
amplitudes, preservation of the ERG signal appears approximately
equal in mice treated at either age, consistent with the similar
extent of structural preservation in the two groups.
Whatever the limitations of AAV5-PDEb therapy, we find that
a combined anti-apoptotic strategy can significantly enhance the
efficacy and duration of therapeutic outcomes. In rd10 mice
injected with both AAV5-PDEb and AAV5-XIAP, the loss of
ONL cells is significantly slower and retinas exhibit higher ERG
responses than retinas treated with AAV5-PDEb alone. In
addition, rd10 mice first treated with AAV5-XIAP at P4, then
subsequently treated with AAV5-PDEb after 2 weeks in the light,
respond with a dramatic slowing of further retinal degeneration
that is not achieved by gene-replacement therapy in animals of the
same age who have not received prior XIAP treatment. However,
under the conditions tested so far, this combination approach does
not rescue ERG responses, even though the production of proteins
involved in visual transduction is increased. This failure appears to
be the consequence of the abnormal morphology of photoreceptor
outer segments that develops when the animals are placed in the
Figure 5. Retinal histology of AAV5-PDEb transduced rd10
retinas. Top Panel. Sub-retinal injection of AAV5-PDEb co-treated
with AAV5-GFP resulted in significant preservation of outer nuclear
layer and inner and outer segment morphology. (GFP, green; PDEb,
red). Bottom Panel. Co-injection with AAV5-XIAP and AAV5-PDEb
shows improved preservation of retinal structures. XIAP (green – via
staining of HA-tag) and PDEb (red) localized to inner and outer
segments, respectively.
doi:10.1371/journal.pone.0037197.g005
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These structural changes in outer segment structure are not seen
when AAV5-PDEb therapy is administered to dark-reared
animals, suggesting a light-dependent aspect to the change in
the cells’ transcription profile and subsequent degeneration.
Despite the absence of ERG responses in the sequentially treated
retinas, it is not clear that there is complete absence of visual
function. In human studies with RPE65 gene-replacement
therapy, there was significant improvement in visual function
despite lack of ERG rescue [5–7]. Thus, more sensitive techniques
for measuring visual function (for example, pupillometry or
psychophysical testing) will be needed to determine the full extent
of visual function rescue achievable using this approach of
photoreceptor preservation with XIAP therapy prior to definitive
rescue with gene-replacement therapy.
A general concern with therapies involving injections into the
subretinal space is the potential damage caused by the creation of
a retinal detachment, which in and of itself can cause outer
segment retraction – a phenomenon that reverses when the retina
becomes reattached [26]. In the case of sub-retinal injection in the
rd10 mice, the detachment was transient, lasting 24–48 hours,
after which AAV5-PDEb treated retinas exhibited relatively
normal appearing outer segments. This suggests that the PDEb
mutation itself, not the creation of the transient detachment, is
responsible for photoreceptor and outer segment loss in rd10 mice,
and that AAV5-XIAP therapy improves cell survival but cannot
overcome loss of an essential outer segment protein. The
mechanism by which the PDEb mutation affects outer segment
formation warrants additional investigation.
In summary, although strategies to block apoptotic cell death
have significant limitations as stand-alone therapies for inherited
retinal degeneration, they appear to enhance rescue by the
corrective gene, as well as permit rescue at older ages than
normally possible, thus effectively extending the window-of-
opportunity for gene-replacement therapy. Our data suggest that
early treatment with AAV5-XIAP could be beneficial, both to
extend the timeline for subsequent gene-replacement therapy and
to increase the long-term efficacy of such treatment. These benefits
need to be weighed against any potential risk of long-term XIAP
overexpression in the retina, as XIAP is a powerful inhibitor of
programmed cell death that could interfere with normal function
or result in transformation events. However, the clear results now
obtained support the continued study of anti-apoptotic therapy as
an adjunctive treatment, particularly given the slow pace at which
Figure 6. ERG analysis of retinal function in rd10 mice treated by co-injection of AAV5-XIAP and AAV5-PDEb.A ,C .Scotopic B wave
responses of treated mice at 0, 1, 2, 3 and 6 weeks after being moved to the light-environment were normalized to the scotopic B wave of untreated
retinas at time 0. Responses in mice treated with AAV5-XIAP plus AAV5-PDEb were greater and maintained longer that those of mice treated with
AAV5-GFP plus AAV5-PDEb. The absence of rescue by AAV5-GFP alone excludes the possibility that rescue results from the surgical procedure alone
or exposure to intact vector. Similar outcomes were obtained in mice treated at P4 and P21. B, D. Representative ERG tracings of rd10 mice treated
with AAV5-XIAP plus AAV5-PDEb, AAV5-GFP plus AAV5-PDEb, or untreated, at 0, 1, 2, 3 and 6 weeks after being moved to the light environment. The
response of untreated retinas at t=0 was larger than the response of treated retinas, presumably because of some deleterious effects caused by the
transient retinal detachment that necessarily accompanies sub-retinal vector injection. Untreated retinas, however, quickly lose all ERG responses,
with no detectable B wave left by 1 week after moving into the light.
doi:10.1371/journal.pone.0037197.g006
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